Bon Secours Liver Institute of Richmond

Recent papers from Bon Secours Liver Institute of Richmond

1. Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trialJournal of Hepatology · 2026
2. Pneumatic Balloon Dilation versus Heller's Myotomy in Pediatric Achalasia: A Systematic Review and Meta-AnalysisEuropean Journal of Pediatric Surgery · 2026
3. Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial.2026
4. The alcohol-associated hepatitis treatment landscapeCurrent Opinion in Gastroenterology · 2026
5. Evidence Supporting Utility of the Oral Cholate Challenge Test of Liver Function and Physiology to Aid Clinical Management: A Review of Analytical and Clinical Validation StudiesGastro Hep Advances · 2026
6. Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trialJournal of Hepatology · 2025
7. Larsucosterol for the Treatment of Alcohol-Associated HepatitisNEJM Evidence · 2025
8. Cholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT ‐V StudyAlimentary Pharmacology & Therapeutics · 2024
9. Safety and efficacy of direct oral anticoagulants in comparison to warfarin in obese patients with atrial fibrillation: A systematic review and meta‐analysisHealth Science Reports · 2024
10. Direct oral anticoagulants (DOAC) versus vitamin K antagonist in left ventricular thrombus: An updated meta‐analysisHealth Science Reports · 2023
11. Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitisAlimentary Pharmacology & Therapeutics · 2023
12. Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedureMedicine · 2023
13. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyHepatology · 2023
14. Eosinophilic esophagitis: A review of the pediatric population and consideration of upcoming therapiesJournal of Gastroenterology and Hepatology · 2021
15. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trialsJournal of Viral Hepatitis · 2021
16. A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH CirrhosisHepatology · 2021
17. A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE StudyHepatology · 2021
18. Performance Characteristics, Intra‐ and Inter‐operator Agreement of Transient Elastography in Pediatric Nonalcoholic Fatty Liver DiseaseJournal of Pediatric Gastroenterology and Nutrition · 2020
19. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal HypertensionGastroenterology · 2019
20. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR TrialsHepatology · 2019